Want to join the conversation?
$HALO 2Q15 Q&A: Fye of JPMorgan asked about starting PD-1 combo study. Helen replied we articulated as part of our strategy a number of quarters ago that both chemo and immunotherapy are going to play important role in non-small cell lung cancer, so planned & developed separate teams to be driving these programs. So they are not in any way related.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.
$RAI has received a $47 billion take over offer from British tobacco giant British American Tobacco! This is huge!
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.